SPRAVATO® (ESKETAMINE)
Overcoming Treatment-Resistant Depression
Pinnacle Care is proud to offer Spravato®, a groundbreaking treatment option for adults living with treatment-resistant depression (TRD) or major depressive disorder (MDD) with suicidal thoughts or actions. Administered under strict clinical supervision in a REMS-certified setting, Spravato represents hope for individuals who haven’t found relief with traditional antidepressants.
WHAT IS SPRAVATO®?
Spravato® (esketamine) is a prescription nasal spray approved by the FDA and used in combination with an oral antidepressant. Unlike traditional antidepressants that can take weeks to build up in the system, Spravato targets different brain pathways and may begin relieving symptoms more rapidly. It is administered in-office under medical supervision and monitored closely due to its dissociative effects.
Spravato is not a take-home medication and can only be given in a certified clinical setting like Pinnacle Care. The treatment is safe, controlled, and follows strict REMS (Risk Evaluation and Mitigation Strategy) guidelines to ensure patient safety and efficacy.
BENEFITS OF
SPRAVATO® TREATMENT
Fast-Acting Relief: Many patients report a noticeable decrease in depressive symptoms in as little as 1–2 treatments.
Improved Outlook: Spravato may enhance mood, motivation, and engagement in daily activities when other treatments have failed.
Reduced Suicidal Thoughts: For those experiencing suicidal ideation, Spravato can offer rapid support during critical periods.
Safe and Supervised Care: Administered in a REMS-certified clinic, patients are monitored before, during, and after treatment.
Personalized Treatment Plans: Every treatment is coordinated with the patient's current mental health provider to ensure seamless, comprehensive care.
WHAT TO EXPECT
Spravato® (esketamine) is administered in a structured and supervised setting to ensure patient safety and optimal outcomes. Treatment is divided into three key phases, with frequency and monitoring tailored to each stage of your progress and clinical response.
Induction Phase (Weeks 1–4)
During the initial phase of treatment, patients receive two in-office treatments per week. This stage is designed to introduce Spravato gradually while providing the brain with consistent exposure to the medication. The goal during this phase is to assess the patient's response to treatment and begin alleviating symptoms of treatment-resistant depression or major depressive disorder with suicidal ideation.
Maintenance Phase (Weeks 5–8)
In the second phase, treatment is typically reduced to once per week. By this point, many patients begin to experience noticeable improvements in mood and overall mental health. This phase focuses on maintaining symptom relief and continuing to monitor safety, effectiveness, and tolerability.
Long-Term Phase (Week 9 and Beyond)
Once stabilized, patients may move to the long-term maintenance phase, where treatment occurs every one to two weeks, depending on their clinical progress and provider recommendations. The frequency is individualized based on how the patient is responding to treatment and their ongoing mental health needs.
IS SPRAVATO® RIGHT FOR YOU?
If you have tried two or more antidepressants without success—or have been diagnosed with MDD, Major Depressive Disorder, accompanied by suicidal thoughts—Spravato may be the next step in your healing journey.
Contact Pinnacle Care today to schedule an appointment and explore whether Spravato may be a good fit for your needs. Our compassionate team will guide you through every step of the process.